Company profile
Sol-Gel Technologies Ltd.
NASDAQ:SLGLBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PATIDEGIB | phase3 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03564145 | phase3 | terminated | 2018-09-12 | 2019-11-13 | Sol-Gel Technologies, Ltd. | A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea |
| NCT00940992 | phase2 | completed | 2012-01-01 | 2012-09-01 | Sol-Gel Technologies, Ltd. | A Study of DER 45-EV Gel to Treat Rosacea |
| NCT04155190 | phase2 | terminated | 2019-12-20 | 2021-04-23 | Sol-Gel Technologies, Ltd. | A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC |
| NCT03564119 | phase3 | completed | 2018-06-21 | 2019-06-10 | Sol-Gel Technologies, Ltd. | A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea |
| NCT03448939 | phase3 | completed | 2018-06-18 | 2019-05-24 | Sol-Gel Technologies, Ltd. | A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea |
FDA applications (0)
No records yet.